期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

二氢嘧啶脱氢酶基因多态性的研究进展 被引量：3

下载PDF
导出
摘要 目的对二氢嘧啶脱氢酶基因(DPYD)多态性的研究情况作一调研和概述。方法查阅近年来国内外有关文献资料,进行整理和归纳。结果与结论DPYD突变是二氢嘧啶脱氢酶活性降低和引起氟化嘧啶类化疗药物毒性的重要原因之一,现已发现40多种DPYD突变或多态性位点。研究DPYD基因多态性,对临床实现个体化治疗,预测氟化嘧啶类化疗药物的毒性危险,有重要意义。
作者 蔡乐 朱珠
机构地区 中国医学科学院-中国协和医科大学北京协和医院药剂科
出处 《中国药学杂志》 CAS CSCD 北大核心 2008年第9期644-648,共5页 Chinese Pharmaceutical Journal
基金 国家自然科学基金资助项目(30640092)
关键词 二氢嘧啶脱氢酶基因 基因多态性 氟化嘧啶类化疗药物 研究进展
分类号 R968 [医药卫生—药理学]
  • 相关文献

参考文献42

  • 1THOMSON MICROMEDEX. MICROMEDEX (R) Healthcare Series [M/CD]. Vol. 128 expires 6/2006. Colorado: Thomson Micromedex, 2006[2006-6-25].
  • 2蔡乐,朱珠.二氢嘧啶脱氢酶及其与5-氟尿嘧啶疗效和毒性的关系[J].中国药学杂志,2007,42(19):1441-1445. 被引量：7
  • 3WEI X, MCLEOD H L,MCMURROUGH J ,et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity [ J ]. J Clin Invest, 1996,98 (3) :610-615.
  • 4JOHNSON M R,WANG K,TILLMANNS S,et al. Structural organization of the human dihydropyrimidine dehydrogenase gene[J]. Cancer Res,1997,57(9) : 1660-1663.
  • 5WEI X,ELIZONDO G,SAPONE A,et al. Characterization of the human dihydropyrimidine dehydrogenase gene [ J ]. Genomics, 1998,51 (3) :391-400.
  • 6VAN KUILENBURG A B,VREKEN P,ABELING N G,et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency [ J ]. Hum Genet, 1999,104 ( 1 ) : 1-9.
  • 7VAN KUILENBURG A B,HAASJES J,RICHEL D J,et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene[J]. Clin Cancer Res,2000,6(12) : 4705-4712.
  • 8VAN KUILENBURG A B,BAARS J W,MEINSMA R,et al. Lethal 5- fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene[J]. Ann Oncol,2003,14(2) :341-342.
  • 9VAN KUILENBURG A B,DOBRITZSCH D,MEINSMA R,et al. Novel disease-causing mutations in the dihyropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure [J]. Biochem J,2002,364(Pt 1) :157-163.
  • 10COLLIE-DUGUID E S ,ETIENNE M C ,MILANO G,et al. Known variant DPYD alleles do not explain DPD deficiency in cancer patients [ J ]. Pharmacogenetics ,2000,10(3) :217-223.

二级参考文献63

  • 1董秋美,何友兼,李苏,周中梅,张力,周志伟,夏忠军,李玉颜.结直肠癌患者DPD水平与5-FU血药浓度、疗效及毒性的相关性研究[J].癌症,2005,24(4):483-487. 被引量：9
  • 2孙燕 ,徐光炜 ,郑树 .口服氟化嘧啶类化疗药的应用进展[J].中国处方药,2005,4(10):26-28. 被引量：1
  • 3Takeda Y, Yoshizaki I, Nonaka Y, et al. Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo. Anticancer Drugs, 2001, 12 (8): 691 ～698
  • 4Kono T, Ishii M, Negoro N, et al. Scleroderma-like reaction induced by uracil-tegafur (UFT) , a second-generation anticancer agent. J Am Acad Dermatol, 2000, 42 (3): 519 -520
  • 5Gardiner S J, Begg E J, Robinson B A. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil. Adverse Drug React Toxicol Rev, 2002, 21 ( 1 - 2):1 - 16
  • 6van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer, 2004, 40(7): 939-950
  • 7Wei X, McLeod H L, McMurrough J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest, 1996, 98 (3): 610 -615
  • 8Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol,2003,8 (3): 132-138
  • 9Hsiao H H, Yang M Y, Chang J G, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwan Residents population.Cancer Chemother Pharmacol. 2004, 53 (5): 445 - 451
  • 10Gross E, Ullrich T, Seck K, et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat, 2003,22 (6): 498-502

共引文献22

同被引文献23

  • 1[3]GAMELIN E,BOISDRON-CELLE M,GUERIN-MEYER V,et al.Correlation between uracil and dihydrouracil plasma ratio,fluorouracil (5-FU) pharmacokinetic parameters,and tolerance in patients with advanced colorectal cancer:A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage[J].J Clin Oncol,1999,17(4):1105-1110.
  • 2[4]JIANG H,LU J,JIANG J,et al.Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidinc pharmacokinetics and pharmacodynamies[J].J Clin Pharmacol,2004,44(11):1260-1272.
  • 3[5]Deporte R,Amiand M,Moreau A,et al.High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma[J].J Chromatngr B Analyt Technol Biomed life Sci,2006,834(1-2):170-177.
  • 4[7]Remaud G,Boiedron-Celle M,Hameline C,et al.An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidinesreiated toxicity in clinical practice[J].J Chromalogr B Analyt Technol Biomed Life Sci,2005,823(2):98-107.
  • 5蔡乐,朱珠.二氢嘧啶脱氢酶及其与5-氟尿嘧啶疗效和毒性的关系[J].中国药学杂志,2007,42(19):1441-1445. 被引量：7
  • 6Keiko Maekawa,Mayumi Saeki,Yoshiro Saito,Shogo Ozawa,Kouichi Kurose,Nahoko Kaniwa,Manabu Kawamoto,Naoyuki Kamatani,Ken Kato,Tetsuya Hamaguchi,Yasuhide Yamada,Kuniaki Shirao,Yasuhiro Shimada,Manabu Muto,Toshihiko Doi,Atsushi Ohtsu,Teruhiko Yoshida,Yasuhiro Matsumura,Nagahiro Saijo,Jun-ichi Sawada. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences[J] 2007,Journal of Human Genetics(10):804～819
  • 7Ron H. N. Schaik. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes[J] 2005,Investigational New Drugs(6):513～522
  • 8董敏,马义德.基于乳腺肿瘤细胞形态特征参数的乳腺癌诊断发展研究[J].中华临床医师杂志:电子版,2013,7(11):5023.
  • 9Gamelin E, Boisdron-Celle M, Gurin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmaeokinetic parameters, and tolerance in patients with advanced colorectat cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage[J]. J Clin Oncol, 1999,17(4):1105.
  • 10Terashima M, Irinoda T, Fujiwara H, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. [J]. Anticancer Res, 2002, 22(2A):761.

引证文献3

二级引证文献7

中国药学杂志
2008年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部